# Opiate Conversion Calculator – Clinical Tool Protocol

**Guidelines Referenced:**  
CDC Guideline for Prescribing Opioids for Chronic Pain 2022, American Pain Society Principles of Analgesic Use 2016, FDA Guidance for Industry on Abuse-Deterrent Opioids 2022, Joint Commission Standards for Pain Assessment and Management 2023

**Official Sources:**  
https://www.cdc.gov/drugoverdose/prescribing/guideline.html  
https://www.americanpainsociety.org/uploads/education/guidelines/chronic-opioid-therapy-cncp.pdf  
https://www.fda.gov/regulatory-information/search-fda-guidance-documents

## CARD INTERFACE LAYOUT

### Card 0 – Dynamic Action Card (Node Dependent)

**Need Opioid Conversion Node:**

~~~
┌─────────────────────────────────────────────────────────────┐
│ OPIOID CONVERSION TYPE SELECTION                            │
├─────────────────────────────────────────────────────────────┤
│ 🔄 CONVERSION INDICATION: Route change for NPO patient      │
│ Current medication: Morphine 30mg PO q4h                   │
│                                                           │
│ ┌─────────────────────────────────┐                        │
│ │     CONVERSION OPTIONS          │                        │
│ │                                │                        │
│ │ ○ ROUTE CHANGE (Same Drug)      │ [Simple ratio conversion]│
│ │   • PO to IV for NPO patients   │ [No cross-tolerance]   │
│ │   • IV to PO for discharge      │ [Standard ratios]      │
│ │   • Apply bioavailability ratios│ [Safety verification] │
│ │                                │                        │
│ │ ○ OPIOID ROTATION (Different)   │ [Cross-tolerance risk] │
│ │   • For side effects/tolerance  │ [25-50% reduction]     │
│ │   • Requires safety reduction   │ [Conservative start]   │
│ │   • Start low, titrate up       │ [Monitor closely]      │
│ │                                │                        │
│ │ ○ LONG-ACTING CONVERSION        │ [Tolerance required]   │
│ │   • Stable chronic pain only    │ [≥60 MME daily]       │
│ │   • Opioid tolerance confirmed  │ [Calculate baseline]   │
│ │   • Calculate total daily MME   │ [Not for acute pain]   │
│ └─────────────────────────────────┘                        │
│                                                           │
│ ⚠️ SAFETY ALERT: Always start conservative with rotations  │
│ Patient factors: Age 65, CrCl 45, no liver disease       │
└─────────────────────────────────────────────────────────────┘
~~~

**Route Conversion Node:**

~~~
┌─────────────────────────────────────────────────────────────┐
│ ROUTE CONVERSION RATIOS                                     │
├─────────────────────────────────────────────────────────────┤
│ SAME OPIOID - DIFFERENT ROUTE                              │
│ Apply bioavailability differences only                     │
│                                                           │
│ ┌─────────────────────────────────┐                        │
│ │     STANDARD RATIOS             │                        │
│ │                                │                        │
│ │ MORPHINE PO:IV = 3:1           │                        │
│ │ Example: 30mg PO = 10mg IV      │                        │
│ │ Calculation: 30mg ÷ 3 = 10mg    │                        │
│ │                                │                        │
│ │ HYDROMORPHONE PO:IV = 4:1       │                        │
│ │ Example: 8mg PO = 2mg IV        │                        │
│ │ Calculation: 8mg ÷ 4 = 2mg      │                        │
│ │                                │                        │
│ │ OXYCODONE PO:IV = 1.5:1         │                        │
│ │ Example: 15mg PO = 10mg IV      │                        │
│ │ Calculation: 15mg ÷ 1.5 = 10mg  │                        │
│ └─────────────────────────────────┘                        │
│                                                           │
│ NO DOSE REDUCTION NEEDED                                   │
│ Same drug = same receptor binding                          │
│ Only bioavailability difference                            │
│                                                           │
│ MONITORING: Same as original medication                    │
│ Expected effect: Equivalent analgesia                      │
└─────────────────────────────────────────────────────────────┘
~~~

**Cross-Tolerance Node:**

~~~
┌─────────────────────────────────────────────────────────────┐
│ OPIOID ROTATION SAFETY REDUCTION                           │
├─────────────────────────────────────────────────────────────┤
│ INCOMPLETE CROSS-TOLERANCE REQUIRES DOSE REDUCTION         │
│                                                           │
│ ┌─────────────────────────────────┐                        │
│ │   REDUCTION RECOMMENDATIONS     │                        │
│ │                                │                        │
│ │ STANDARD REDUCTION: 25-50%      │                        │
│ │ Use 75% of calculated dose      │                        │
│ │                                │                        │
│ │ HIGHER REDUCTION (50%) if:      │                        │
│ │ • Age >65 years                 │                        │
│ │ • CrCl <30 mL/min              │                        │
│ │ • Multiple sedatives           │                        │
│ │ • Liver disease (Child B/C)    │                        │
│ │ • Frail/debilitated            │                        │
│ │                                │                        │
│ │ TITRATION SCHEDULE:             │                        │
│ │ • Start at reduced dose         │                        │
│ │ • Titrate every 24-48 hours     │                        │
│ │ • Have breakthrough available   │                        │
│ │ • Monitor for side effects      │                        │
│ └─────────────────────────────────┘                        │
│                                                           │
│ RATIONALE: Different opioids have varying receptor        │
│ affinities and individual pharmacogenomic responses       │
│                                                           │
│ SAFETY MONITORING:                                         │
│ • Respiratory rate, sedation level                        │
│ • Pain scores, functional improvement                      │
│ • Side effects (nausea, constipation)                     │
└─────────────────────────────────────────────────────────────┘
~~~

### Card 1 – Static Assessment/MME Conversion Factors

~~~
┌─────────────────────────────────────────────────────────────┐
│ MORPHINE MILLIGRAM EQUIVALENTS (MME) FACTORS               │
├─────────────────────────────────────────────────────────────┤
│ 📊 ORAL OPIOID CONVERSION FACTORS:                         │
│                                                           │
│ WEAK OPIOIDS:                                              │
│ • Codeine: 0.15 (30mg codeine = 4.5 MME)                  │
│ • Tramadol: 0.1 (100mg tramadol = 10 MME)                 │
│                                                           │
│ MODERATE OPIOIDS:                                          │
│ • Morphine: 1.0 (baseline comparison)                      │
│ • Hydrocodone: 1.0 (10mg = 10 MME)                        │
│ • Oxycodone: 1.5 (10mg = 15 MME)                          │
│                                                           │
│ STRONG OPIOIDS:                                            │
│ • Hydromorphone: 4.0 (2mg = 8 MME)                        │
│ • Oxymorphone: 3.0 (5mg = 15 MME)                         │
│ • Methadone: Variable (see complex dosing)                │
│                                                           │
│ TRANSDERMAL FENTANYL:                                      │
│ • Conversion factor: 2.4                                   │
│ • 12 mcg/hr patch = 28.8 MME daily                        │
│ • 25 mcg/hr patch = 60 MME daily                          │
│ • 50 mcg/hr patch = 120 MME daily                         │
│ • 75 mcg/hr patch = 180 MME daily                         │
│ • 100 mcg/hr patch = 240 MME daily                        │
│                                                           │
│ ⚠️ METHADONE SPECIAL DOSING:                               │
│ Complex pharmacokinetics require specialist consultation   │
│ • <30 MME daily: 4:1 ratio (morphine:methadone)           │
│ • 30-99 MME daily: 8:1 ratio                              │
│ • ≥100 MME daily: 12:1 ratio                              │
│ • Always reduce by 75-90% and titrate slowly              │
└─────────────────────────────────────────────────────────────┘
~~~

### Card 2 – Static Physical Exam/Special Populations

~~~
┌─────────────────────────────────────────────────────────────┐
│ SPECIAL POPULATIONS & SAFETY CONSIDERATIONS                │
├─────────────────────────────────────────────────────────────┤
│ 🔍 PRE-CONVERSION ASSESSMENT:                              │
│ • Current pain level, functional status                    │
│ • Respiratory rate, oxygen saturation                      │
│ • Mental status, sedation level                            │
│ • Vital signs, renal/hepatic function                      │
│                                                           │
│ 👴 ELDERLY PATIENTS (>65 years):                           │
│ • Start 25-50% lower than calculated dose                  │
│ • Longer dosing intervals initially                        │
│ • Avoid long-acting formulations initially                 │
│ • Higher risk of falls, confusion, constipation            │
│                                                           │
│ 🩺 RENAL IMPAIRMENT:                                       │
│ • CrCl <30: Avoid morphine, codeine (toxic metabolites)   │
│ • Safe options: Fentanyl, methadone, buprenorphine        │
│ • Caution with hydromorphone (reduce dose 50%)            │
│ • Monitor for prolonged effects                            │
│                                                           │
│ 🫀 HEPATIC IMPAIRMENT:                                     │
│ • Child-Pugh B/C: Reduce doses 25-50%                     │
│ • Increase dosing intervals                                │
│ • Avoid long-acting formulations                           │
│ • Monitor sedation closely                                 │
│                                                           │
│ 🚫 OPIOID-NAIVE PATIENTS:                                  │
│ Never initiate with:                                       │
│ • Fentanyl patches (requires tolerance)                    │
│ • Methadone (complex dosing)                               │
│ • Extended-release formulations                            │
│ • Start with immediate-release, low doses                  │
│                                                           │
│ ⚠️ DRUG INTERACTIONS:                                       │
│ • Benzodiazepines: Increase respiratory depression         │
│ • SNRIs: Risk of serotonin syndrome                        │
│ • CYP3A4 inhibitors: Affect fentanyl/methadone levels     │
│ • Monitor closely with any CNS depressants                 │
└─────────────────────────────────────────────────────────────┘
~~~

## FLOWCHART (Algorithm Decision Tree)

~~~mermaid
graph TD
    A[Need Opioid Conversion] --> B{Conversion Type?}
    
    B -->|Route Change| C[Apply Standard Ratios Same Drug]
    B -->|Opioid Rotation| D[Calculate MME Different Drug]
    B -->|Long-Acting| E[Assess Opioid Tolerance]
    
    C --> F[No Dose Reduction Needed]
    
    D --> G[Apply 25-50% Safety Reduction]
    
    E --> H{≥60 MME Daily?}
    
    H -->|Yes| I[Calculate Patch/LA Dose]
    H -->|No| J[Not Candidate Use IR Only]
    
    F --> K[Implement New Regimen Monitor]
    G --> L[Start Conservative Titrate Up]
    I --> M[Overlap Period 12-18hr]
    
    K --> N{Adequate Analgesia?}
    L --> N
    M --> N
    
    N -->|Yes| O[Continue Current Regimen]
    N -->|No| P[Assess for Adjustment]
    
    P --> Q{Side Effects Present?}
    
    Q -->|Yes| R[Reduce Dose or Change Agent]
    Q -->|No| S[Increase Dose by 25-50%]
    
    R --> T[Monitor Response]
    S --> T
    
    T --> U{Goal Achieved?}
    
    U -->|Yes| V[Stable Regimen Reached]
    U -->|No| W[Reassess Strategy]
~~~

## NODE-TO-DYNAMIC CARD PROMPT MAPPING (WITH INTERACTIVES)

| **Step (Node)**                    | **Dynamic Card Prompt/Question**                                                                 | **Interactive Components**                                        |
|-------------------------------------|--------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|
| Need Conversion Recognition         | "Opioid conversion required. Select conversion type: route change, rotation, or long-acting?"   | [Conversion Type Selection], [Patient Assessment], [History Review]|
| Route Change Pathway                | "Same opioid, different route selected. Apply standard bioavailability ratios?"                | [Ratio Calculator], [Dose Verification], [No Reduction Needed]    |
| Opioid Rotation Pathway             | "Converting to different opioid. Calculate MME and apply safety reduction?"                     | [MME Calculator], [Safety Reduction], [Cross-Tolerance Warning]   |
| Long-Acting Assessment              | "Long-acting conversion requested. Confirm opioid tolerance ≥60 MME daily?"                     | [Tolerance Verification], [Daily MME Total], [Candidacy Check]    |
| MME Calculation                     | "Calculate total daily MME using conversion factors for current regimen?"                       | [Drug Selection], [Dose Entry], [MME Calculator], [Risk Level]    |
| Safety Reduction Application        | "Apply 25-50% reduction for opioid rotation based on patient risk factors?"                    | [Risk Assessment], [Reduction Calculator], [Patient Factors]      |
| Route Ratio Application             | "Apply standard PO:IV ratios for route conversion without dose reduction?"                     | [Ratio Selection], [Calculation Display], [Dose Confirmation]     |
| Long-Acting Calculation             | "Calculate long-acting dose with appropriate overlap period for transition?"                    | [LA Dosing], [Overlap Timer], [Transition Protocol]               |
| Implementation Monitoring           | "New regimen implemented. Monitor for efficacy and side effects?"                              | [Pain Assessment], [Side Effect Check], [Monitoring Schedule]     |
| Efficacy Assessment                 | "Evaluate pain control and functional improvement with new regimen?"                           | [Pain Scores], [Function Scale], [Patient Satisfaction]          |
| Dose Adjustment Decision            | "Inadequate analgesia identified. Assess for dose increase or alternative strategy?"           | [Adjustment Calculator], [Alternative Options], [Safety Check]    |
| Side Effect Management              | "Side effects present. Consider dose reduction or agent change?"                               | [Side Effect Assessment], [Dose Reduction], [Alternative Agents]  |
| Titration Protocol                  | "Adjust dose by 25-50% based on response. Schedule next assessment?"                          | [Titration Calculator], [Schedule Next], [Monitoring Alerts]      |

**Interactive Highlights:**  
- MME calculator: real-time total with risk level display
- Conversion calculator: automated dose calculations with safety verification
- Patient risk assessment: interactive screening for reduction factors
- Monitoring scheduler: automated follow-up reminders and assessment prompts
- Drug interaction checker: alerts for dangerous combinations

## INTERACTIVE ELEMENTS

### Quick MME Calculator

~~~
┌─────────────────────────────────────────┐
│         TOTAL DAILY MME CALCULATOR      │
├─────────────────────────────────────────┤
│ Enter Current Medications:              │
│                                         │
│ Drug         Dose      × Factor = MME   │
│ Oxycodone   [20mg q6h] × 1.5   = 120   │
│ Tramadol    [100mg BID] × 0.1   = 20    │
│ Morphine    [15mg q4h] × 1.0   = 90     │
│                                         │
│ TOTAL DAILY MME: 230                    │
│                                         │
│ 🔴 RISK LEVEL: HIGH (>90 MME)           │
│ • Increased overdose risk                │
│ • Consider dose reduction               │
│ • Enhanced monitoring required          │
│                                         │
│ [ADD MEDICATION] [CALCULATE] [RESET]    │
└─────────────────────────────────────────┘
~~~

### Opioid Rotation Calculator

~~~
┌─────────────────────────────────────────┐
│      OPIOID ROTATION CALCULATOR         │
├─────────────────────────────────────────┤
│ FROM: Morphine 180 MME daily            │
│ TO: Hydromorphone                       │
│                                         │
│ CALCULATION STEPS:                      │
│ Step 1: Current MME = 180               │
│ Step 2: Convert factor (÷4) = 45mg      │
│ Step 3: Safety reduction (×0.75) = 34mg │
│ Step 4: Round down = 30mg daily         │
│                                         │
│ NEW REGIMEN SUGGESTION:                 │
│ Hydromorphone 5mg PO q6h                │
│ (Total: 20mg daily for safety)         │
│                                         │
│ BREAKTHROUGH:                           │
│ Hydromorphone 1mg PO q2h PRN            │
│ (10% of daily dose)                     │
│                                         │
│ ⚠️ Start conservative, titrate up        │
│                                         │
│ [CALCULATE ROTATION] [PRINT ORDERS]     │
└─────────────────────────────────────────┘
~~~

### Fentanyl Patch Converter

~~~
┌─────────────────────────────────────────┐
│     FENTANYL PATCH CALCULATOR           │
├─────────────────────────────────────────┤
│ Current total MME: 180 from PO opioids  │
│                                         │
│ PATCH CONVERSION:                       │
│ 180 MME ÷ 2.4 = 75 mcg/hr              │
│                                         │
│ RECOMMENDED PATCH: 50-75 mcg/hr         │
│ Start with: 50 mcg/hr (conservative)    │
│                                         │
│ TRANSITION PROTOCOL:                    │
│ • Apply patch, continue PO × 12 hours   │
│ • Then discontinue oral opioids         │
│ • Full effect achieved in 24-48 hours   │
│                                         │
│ BREAKTHROUGH COVERAGE:                  │
│ Morphine 15mg PO q2h PRN                │
│ (10% of daily MME requirement)          │
│                                         │
│ ⚠️ REQUIRES OPIOID TOLERANCE             │
│ Never use in opioid-naive patients      │
│                                         │
│ [CALCULATE PATCH] [TRANSITION ORDERS]   │
└─────────────────────────────────────────┘
~~~

### Special Population Dosing Assistant

~~~
┌─────────────────────────────────────────┐
│    SPECIAL POPULATION DOSE ADJUSTOR     │
├─────────────────────────────────────────┤
│ PATIENT FACTORS:                        │
│ Age: 78 years ⚠️                        │
│ CrCl: 35 mL/min ⚠️                      │
│ Liver: Normal ✓                         │
│ Concurrent sedatives: Lorazepam ⚠️       │
│                                         │
│ RISK FACTORS IDENTIFIED: 3              │
│                                         │
│ RECOMMENDED ADJUSTMENTS:                │
│ • Reduce calculated dose by 50%         │
│ • Start with longer intervals           │
│ • Avoid long-acting formulations        │
│ • Enhanced monitoring required          │
│                                         │
│ STANDARD DOSE: 30mg daily               │
│ ADJUSTED DOSE: 15mg daily               │
│                                         │
│ SUGGESTED REGIMEN:                      │
│ Morphine 2.5mg PO q6h                   │
│ Breakthrough: 2.5mg PO q2h PRN          │
│                                         │
│ [APPLY ADJUSTMENTS] [PRINT PROTOCOL]    │
└─────────────────────────────────────────┘
~~~

## VIRTUA VOORHEES PAIN MANAGEMENT ADDENDA

- **Pain Service Consultation:** 24/7 availability via Transfer Center 856-886-5111 for complex conversions and high-risk patients
- **Pharmacy Clinical Support:** Dedicated pain pharmacist available for dosing verification and drug interaction screening
- **Quality Metrics:** Conversion accuracy rates, patient safety events, pain control effectiveness, opioid stewardship compliance
- **Electronic Calculator Integration:** Built-in EMR calculator tools with automatic alerts for high-risk conversions and interactions

## REFERENCE (GUIDELINE & SOURCE)
Centers for Disease Control and Prevention. CDC Clinical Practice Guideline for Prescribing Opioids for Chronic Pain. 2022.  
https://www.cdc.gov/drugoverdose/prescribing/guideline.html

**Additional References:**  
American Pain Society. Principles of Analgesic Use. 8th Edition. 2016.  
https://www.americanpainsociety.org/uploads/education/guidelines/chronic-opioid-therapy-cncp.pdf

Joint Commission. Standards for Pain Assessment and Management. 2023.  
https://www.jointcommission.org/standards/standard-faqs/hospital-and-hospital-clinics/

Food and Drug Administration. Guidance for Industry: Abuse-Deterrent Opioids. 2022.  
https://www.fda.gov/regulatory-information/search-fda-guidance-documents

**All calculations follow evidence-based conversion protocols with mandatory safety reductions for opioid rotations and enhanced monitoring for high-risk populations to ensure safe and effective pain management.**
